October 08, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Akebia Therapeutics Inc (NASDAQ:AKBA) shares over potential securities laws violations by Akebia Therapeutics and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Akebia Therapeutics Inc (NASDAQ:AKBA) concerning whether a series of statements by Akebia Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On July 24, 2013, Akebia Therapeutics announces the initiation of phase 2b trial of Oral Anemia Candidate. Akebia Therapeutics Inc saidthat it has dosed the first patient in the Phase 2b trial of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD). AKB-6548 is an orally available, hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, which is designed to stabilize HIF2?, a critical regulator of red blood cell production and iron absorption.

On March 20, 2104, Akebia Therapeutics Inc announced the pricing of its initial public offering of 5,882,353 shares of common stock at an initial public offering price of $17.00 per share.

Shares of Akebia Therapeutics Inc (NASDAQ:AKBA) reached $29.17 per share in June 2014.

On October 27, 2014, Akebia Therapeutics Inc announced positive top-line results from its Phase 2b placebo-controlled trial of AKB-6548 in non-dialysis patients with anemia related to chronic kidney disease.


Shares of Akebia Therapeutics Inc (NASDAQ:AKBA) declined from over $29 per share in June 2014 to as low as $6.65 per share in August 2015.